Michael Albosta1,2, Jesse Bakke3. 1. Central Michigan University College of Medicine, 1200 S. Franklin St., Mount Pleasant, MI, 48858, USA. albos1ms@cmich.edu. 2. , Saginaw, MI, 48602, USA. albos1ms@cmich.edu. 3. Central Michigan University College of Medicine, 1200 S. Franklin St., Mount Pleasant, MI, 48858, USA.
Abstract
BACKGROUND: Type 2 Diabetes is a metabolic disorder characterized by hyperglycemia that causes numerous complications with significant long-term morbidity and mortality. The disorder is primarily due to insulin resistance particularly in liver, skeletal muscle, and adipose tissue. In this review, we detail the hormonal mechanisms leading to the development of diabetes and discuss whether intermittent fasting should be considered as an alternative, non-medicinal treatment option for patients with this disorder. METHODS: We searched PubMed, Ovid MEDLINE, and Google Scholar databases for review articles, clinical trials, and case series related to type 2 diabetes, insulin resistance, and intermittent fasting. Articles were carefully reviewed and included based on relevance to our topic. We excluded abstracts and any non-English articles. RESULTS: The majority of the available research demonstrates that intermittent fasting is effective at reducing body weight, decreasing fasting glucose, decreasing fasting insulin, reducing insulin resistance, decreasing levels of leptin, and increasing levels of adiponectin. Some studies found that patients were able to reverse their need for insulin therapy during therapeutic intermittent fasting protocols with supervision by their physician. CONCLUSION: Current evidence suggests that intermittent fasting is an effective non-medicinal treatment option for type 2 diabetes. More research is needed to delineate the effects of intermittent fasting from weight loss. Physicians should consider educating themselves regarding the benefits of intermittent fasting. Diabetic patients should consult their physician prior to beginning an intermittent fasting regimen in order to allow for appropriate oversight and titration of the patients medication regimen during periods of fasting.
BACKGROUND:Type 2 Diabetes is a metabolic disorder characterized by hyperglycemia that causes numerous complications with significant long-term morbidity and mortality. The disorder is primarily due to insulin resistance particularly in liver, skeletal muscle, and adipose tissue. In this review, we detail the hormonal mechanisms leading to the development of diabetes and discuss whether intermittent fasting should be considered as an alternative, non-medicinal treatment option for patients with this disorder. METHODS: We searched PubMed, Ovid MEDLINE, and Google Scholar databases for review articles, clinical trials, and case series related to type 2 diabetes, insulin resistance, and intermittent fasting. Articles were carefully reviewed and included based on relevance to our topic. We excluded abstracts and any non-English articles. RESULTS: The majority of the available research demonstrates that intermittent fasting is effective at reducing body weight, decreasing fasting glucose, decreasing fasting insulin, reducing insulin resistance, decreasing levels of leptin, and increasing levels of adiponectin. Some studies found that patients were able to reverse their need for insulin therapy during therapeutic intermittent fasting protocols with supervision by their physician. CONCLUSION: Current evidence suggests that intermittent fasting is an effective non-medicinal treatment option for type 2 diabetes. More research is needed to delineate the effects of intermittent fasting from weight loss. Physicians should consider educating themselves regarding the benefits of intermittent fasting. Diabeticpatients should consult their physician prior to beginning an intermittent fasting regimen in order to allow for appropriate oversight and titration of the patients medication regimen during periods of fasting.
Authors: Michelle Harvie; Claire Wright; Mary Pegington; Debbie McMullan; Ellen Mitchell; Bronwen Martin; Roy G Cutler; Gareth Evans; Sigrid Whiteside; Stuart Maudsley; Simonetta Camandola; Rui Wang; Olga D Carlson; Josephine M Egan; Mark P Mattson; Anthony Howell Journal: Br J Nutr Date: 2013-04-16 Impact factor: 3.718
Authors: Sofia Cienfuegos; Kelsey Gabel; Faiza Kalam; Mark Ezpeleta; Eric Wiseman; Vasiliki Pavlou; Shuhao Lin; Manoela Lima Oliveira; Krista A Varady Journal: Cell Metab Date: 2020-07-15 Impact factor: 31.373
Authors: Shameena Gill; Alia Maisara Adenan; Adli Ali; Noor Akmal Shareela Ismail Journal: Int J Environ Res Public Health Date: 2022-01-06 Impact factor: 3.390